ILMN:NGS-Illumina Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 124.39

Change

0.00 (0.00)%

Market Cap

USD 19.79B

Volume

1.38M

Analyst Target

USD 347.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-08 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 34.17B
ICLR ICON PLC

N/A

USD 18.82B
NTRA Natera Inc

N/A

USD 15.36B
EXAS EXACT Sciences Corporation

N/A

USD 13.02B
MEDP Medpace Holdings Inc

N/A

USD 9.93B
RDNT RadNet Inc

N/A

USD 5.00B
SHC Sotera Health Co

N/A

USD 4.49B
NEOG Neogen Corporation

N/A

USD 3.13B
VCYT Veracyte Inc

N/A

USD 2.59B
GH Guardant Health Inc

N/A

USD 2.52B

ETFs Containing ILMN

CURG:LSE VanEck Genomics and Healt.. 6.29 % 0.00 %

N/A

USD 5.12M
BIS ProShares UltraShort Nasd.. 5.67 % 0.95 %

N/A

USD 3.52M
CURE:XETRA VanEck Genomics and Healt.. 5.36 % 0.00 %

N/A

N/A
QQQA ProShares Nasdaq-100 Dors.. 4.71 % 0.00 %

N/A

USD 0.01B
EKG First Trust Nasdaq Lux Di.. 4.48 % 0.00 %

N/A

USD 2.46M
EDOC Global X Telemedicine & D.. 4.43 % 0.00 %

N/A

USD 0.04B
EDOC:LSE Global X Telemedicine & D.. 4.38 % 0.00 %

N/A

USD 3.69M
EDOG:LSE Global X Telemedicine & D.. 4.38 % 0.00 %

N/A

USD 0.38M
GNOG:LSE Global X Genomics & Biote.. 4.36 % 0.00 %

N/A

USD 5.77M
XGES:LSE Xtrackers MSCI Genomic He.. 4.12 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 4.04 % 0.35 %

N/A

USD 0.43B
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.84 % 0.00 %

N/A

N/A
PAMC Pacer Lunt MidCap Multi-F.. 3.22 % 0.00 %

N/A

USD 0.06B
CDNA:CA CI Bio-Revolution Index E.. 2.95 % 0.00 %

N/A

CAD 5.99M
2B70:F iShares NASDAQ US Biotech.. 2.34 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 2.34 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 2.34 % 0.00 %

N/A

USD 0.04B
QQXT First Trust NASDAQ-100 Ex.. 1.91 % 0.60 %

N/A

USD 0.12B
DOCG:LSE L&G Healthcare Breakthrou.. 1.90 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.90 % 0.00 %

N/A

USD 0.07B
2B78:XETRA iShares Healthcare Innova.. 1.88 % 0.00 %

N/A

USD 1.14B
BTEC:SW iShares Nasdaq US Biotech.. 1.73 % 0.00 %

N/A

N/A
ROBO:LSE L&G ROBO Global Robotics .. 1.68 % 0.00 %

N/A

USD 0.70B
ROBE:LSE L&G ROBO Global Robotics .. 1.67 % 0.00 %

N/A

USD 0.70B
ROBG:LSE L&G ROBO Global Robotics .. 1.67 % 0.00 %

N/A

USD 0.70B
ROBO Robo Global® Robotics an.. 1.66 % 0.00 %

N/A

USD 1.08B
ROBO Robo Global® Robotics an.. 1.66 % 0.95 %

N/A

USD 1.08B
HEAL:SW iShares Healthcare Innova.. 1.65 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 1.64 % 0.95 %

N/A

USD 0.08B
EQUL IndexIQ ETF Trust - IQ En.. 1.49 % 0.00 %

N/A

USD 7.29M
QQQE Direxion NASDAQ-100 Equal.. 1.08 % 0.35 %

N/A

USD 1.28B
SPMD SPDR Russell Small Cap Co.. 0.80 % 0.06 %

N/A

USD 11.55B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.71 % 0.00 %

N/A

USD 2.76B
SPY4:SW SPDR® S&P 400 US Mid Cap.. 0.71 % 0.00 %

N/A

USD 2.85B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.71 % 0.24 %

N/A

USD 22.96B
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.62 % 0.00 %

N/A

N/A
MVV ProShares Ultra MidCap400 0.58 % 0.95 %

N/A

USD 0.14B
MIDU Direxion Daily Mid Cap Bu.. 0.57 % 1.10 %

N/A

USD 0.08B
UMDD ProShares UltraPro MidCap.. 0.42 % 0.95 %

N/A

USD 0.03B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 2.57B
ALFA 0.00 % 0.65 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.19B
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
IJJ iShares S&P Mid-Cap 400 V.. 0.00 % 0.25 %

N/A

USD 7.73B
IVOV Vanguard S&P Mid-Cap 400 .. 0.00 % 0.20 %

N/A

USD 0.93B
MDYV SPDR® S&P 400 Mid Cap Va.. 0.00 % 0.15 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
QQEW First Trust NASDAQ-100 Eq.. 0.00 % 0.60 %

N/A

USD 1.92B
BTEC 0.00 % 0.42 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.08B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.05B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

N/A

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

N/A
ZMID:CA BMO S&P US Mid Cap Index .. 0.00 % 0.00 %

N/A

N/A
ROBO:AU ETFS ROBO Global Robotics.. 0.00 % 0.00 %

N/A

USD 0.23B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 5.39M
BBIG:CA 0.00 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
DDOC:F Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 4.62M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.67% 53% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.67% 53% F 39% F
Trailing 12 Months  
Capital Gain -21.45% 49% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.45% 49% F 32% F
Trailing 5 Years  
Capital Gain -54.94% 42% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.94% 42% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -15.23% 36% F 21% F
Dividend Return -15.23% 36% F 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.43% 86% B+ 56% F
Risk Adjusted Return -45.55% 28% F 19% F
Market Capitalization 19.79B 95% A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 45.90 22% 12%
Price/Book Ratio 14.45 12% 8%
Price / Cash Flow Ratio 42.94 9% 6%
Price/Free Cash Flow Ratio 51.88 5% 6%
Management Effectiveness  
Return on Equity -76.19% 37% 24%
Return on Invested Capital -13.44% 66% 36%
Return on Assets 1.44% 87% 71%
Debt to Equity Ratio 25.92% 68% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector